At this year’s Society of Nuclear Medicine and Molecular Imaging, SNMMI, Annual Meeting, GE HealthCare (GEHC) is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. “Precision care is the future of oncology-and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,” shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. “With tools like GE HealthCare’s Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry-ultimately helping improve outcomes for our patients. This is precision care in action, and it’s making a real difference in patients’ lives.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- Positive Outlook for GE Healthcare Technologies Amid Strong U.S. Hospital Expenditure and Global Stabilization
- GE Healthcare Issues $1.5 Billion in Senior Notes
- GE Healthcare Announces $1.5 Billion Notes Offering
- GE HealthCare announces NCCN Guidelines recommend use of FES PET imaging
- GE Healthcare Holds Annual Stockholders Meeting